Johnson DE, McIntyre RS, Mansur RB, Rosenblat JD (2023)
An update on potential pharmacotherapies for cognitive impairment in bipolar disorder
Expert Opin Pharmacother

Lowe JA, 3rd, DeNinno SL, Coe JW, Zhang L, Mente S, Hurst RS, Mather RJ, Ward KM, Shrikhande A, Rollema H, Johnson DE, Horner W, Gorczyca R, Tingley FD, 3rd, Kozak R, Majchrzak MJ, Tritto T, Sadlier J, Shaffer CL, Ellerbrock B, Osgood SM, MacDougall MC, McDowell LL (2010)
A novel series of [3.2.1] azabicyclic biaryl ethers as alpha3beta4 and alpha6/4beta4 nicotinic receptor agonists
Bioorganic & Medicinal Chemistry Lett 20: 4749

Rollema H, Hajos M, Seymour PA, Kozak R, Majchrzak MJ, Guanowsky V, Horner WE, Chapin DS, Hoffmann WE, Johnson DE, McLean S, Freeman J, Williams KE (2009)
Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition
Biochemical Pharmacology 78: 813

Johnson DE, Nedza FM, Spracklin DK, Ward KM, Schmidt AW, Iredale PA, Godek DM, Rollema H (2005)
The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine release
European Journal of Pharmacology 506: 209

Johnson DE, Seidler FJ, Slotkin TA (1998)
Early biochemical detection of delayed neurotoxicity resulting from developmental exposure to chloropyrifos
Brain Research Bulletin 45: 143